This study highlighted the effects of Esc against CRC and clarified that Esc inhibits the PI3K/Akt/mTOR signaling pathway and enhances the anti-CRC activity by binding to ENO1, suggesting that ENO1 may become a potential target for the treatment of CRC. The gene discussed is AKT1; the disease is colorectal carcinoma.